December 13, 2011

Winning against cardiovascular complications in Type 1 Diabetes


JDRF is currently investigating whether metformin—a drug commonly used to treat type 2 diabetes—could help prevent or reduce the risk of cardiovascular complications in people with type 1 diabetes.

The study, named REMOVAL (REducing with MetfOrmin Vascular Adverse Lesions), has begun enrollment. The REMOVAL study is a multi-center, international trial that will study 500 patients with type 1 diabetes aged 40 years or older, and will take place in five countries: the United Kingdom, Canada, Australia, Denmark, and the Netherlands.

Using metformin as a means to reduce the conditions that may lead to cardiovascular complications is a safer bet. Metformin   reduces the amount of sugar made by the liver, limits the amount of sugar absorbed into the body from the diet, and makes insulin receptors more sensitive. Is insulin sensitivity a problem for most people with type 1 diabetes? Nevertheless – metformin does not increase the amount of insulin produced by the body.

As mentioned previously about the study criteria, participants are 40 years and older. Hopefully by the time I reach the forty and up crowd – the results of this study will be winning effort or an epic failure.

To learn more about the REMOVAL study, see the site.